___

• http://whqlibdoc.who.int/publications/2009/9789283204237_tur_p1-104.pdf
• http://www.kanser.gov.tr/folders/file/8iL-2006-SON.pdf
• Kutluk T., Kars A. (Editörler) , Kanser Konusunda Genel Bilgiler, Ankara, Türk Kanser Araştırma ve Savaş Kurumu Yayınları, (1994), sayfa 26 .
• www.cancervic.org.au/downloads/other_languages/turkish/Cancer_WhatIs.pdf
• http://www.cancer.gov/cancertopics/understandingcancer/cancergenomics/page49
• Vogelstein B., Kinzler K.W.: Cancer genes and the pathways they control, Nat Med, 10, 789 (2004).
• http://tr.wikipedia.org/wiki/P53
• http://www.cancer.gov/cancertopics/factsheet/Sites-Types/metastatic
• Hart, I. R., “Metastasis”, Souhami R. L., Tannock, I., Hohenberger, P., Horiot, J.C. (Eds), Oxford Textbook of Oncology Second Edition, New York, Oxford University Press, (2002), cilt I, sayfa 103.
• http://en.wikipedia.org/wiki/Radiation_therapy
• Greish, K.: Enhanced permeability and retention of macromolecular drugs in solid tumors: A royal gate for targeted anticancer nanomedicines, J Drug Target, 15, 457 (2007).
• Leaf, C.: Why we are losing the war on cancer (and how to win it) , Fortune, 149, 84 (2004).
• Jain, R. K.: Molecular regulation of vessel maturation, Nat Med, 9, 685 (2003).
• Hashizume, H., Baluk, P., Morikawa, S., McLean, J. W., Thurston, G., Roberge, S., Jain, R. K., McDonald, D. M.: Openings between defective endothelial cells explain tumor vessel leakiness, Am J Pathol , 156, 1363 (2000).
• Yuan, F., Dellian, M., Fukumura, D., Leunig, M., Berk, D. A., Torchilin, V. P., Jain, R. K.: Vascular permeability in a human tumor xenograft: Molecular size dependence and cutoff size, Cancer Res , 55, 3752 (1995).
• Wu, J., Akaike, T., Maeda, H.: Modulation of enhanced vascular permeability in tumors by a bradykinin antagonist, a cyclooxygenase ınhibitor, and a nitric oxide scavenger, Cancer Res, 58 (1998).
• Kopecek, J., Kopeckova, P., Minko, T., Lu, Z.R., Peterson, C.M.: Water soluble polymers in tumor targeted delivery, J Control Release, 74, 147 (2001).
• Alberto, A., Gabizon, M. D. : Pegylated liposomal doxorubicin: Metamorphosis of an old drug into a new form of chemotherapy, Cancer Invest , 19, 424 (2001).
• Matsumura, Y., Maeda, H.: A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs, Cancer Res, 46, 6387 (1986).
• Fukumura, D., Jain, R. K.: Tumor microvasculature and microenvironment: Targets for antiangiogenesis and normalization, Microvasc Res, 74, 72 (2007).
• Harris, A. L.: Hypoxia - a key regulatory factor in tumour growth, Nat Rev Cancer, 2, 38 (2002).
• Tatum, J. L. et al.: Hypoxia: Importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy, Int J Radiat Biol, 82, 699 (2006).
• Lammers, T., Hennink, W.E., Storm, G.: Tumour targeted nanomedicines: Principles and practice, Brit J Cancer, 99, 392 (2008).
• Kaş, H. S., Eldem, T., “Kontrollü Salım Sistemlerinin Hedeflendirilmesi”, Gürsoy, A. (Editör), Kontrollü Salım Sistemleri, İstanbul, Kontrollü Salım Sistemleri Derneği Yayı- nı, (2002), sayfa 308.
• Gürsoy, R. N., Siahann, T. J.: Binding and internalization of ICAM – 1 peptide by the surface receptors of T cells, J Pep Res, 53, 414 (1999).
• Ghose, T., The Current Status of Tumor Targeting: A Rewiev, Page, M. (Editör), Tumor Targeting in Cancer Therapy, New Jersey, Humana Press, (2002), sayfa 5.
• Malam, Y., Loizido, M., Seifalian, A. M.: Liposomes and nanoparticles: nanosized ve- hicles for drug delivery in cancer, Trends Pharmacol Sci, 30, 592 (2009).
• Nielsen, U. B., Marks, J. D.: Internalizing antibodies and targeted cancer therapy: di- rect selection from phage display libraries, Pharm Sci Technol Today, 3, 282 (2000).
• Bernold, D.M., Sinicrope, F.A.: Kolorektal kanser kemoterapisinde gelişmeler,Clinical Gastroenterology and Hepatology, Turkish edition, 1, 126 (2006).
• Aina, O. H., Sroka, T. C., Chen, M. L., Lam, K. S.: Therapeutic cancer targeting pep- tides, Biopolymers , 66, 184 (2002).
• Shadidi, M., Sioud, M.: Selective targeting of cancer cells using synthetic peptides, Drug Resist Update, 6, 363 (2003).
• Enback, J., Laakkonen, P.: Tumour-homing peptides: tools for targeting, imaging and destruction, Biochem Soc T, 35, 780 (2007).
• Akerman, M. E., Chan, W. C. W., Laakkonen, P., Bhatia, S. N., Ruoslahti, E.: Nanocrys- tal targeting in vivo, P Natl Acad Sci, 99, 12617 (2002).
• Karmali, P. P., Kotamraju, V. R., Kastantin, M., Black, M., Missirlis, D., Tirrell, M., Ruoslahti, E.: Targeting of albumin-embedded paclitaxel nanoparticles to tumors, Nanomedicine: NBM, 5, 73 (2009).
• New R.R.C., (Editör), Liposomes: a practical approach, New York, Oxford University Press, (1990).
• Zelphati, O., Szoka, F.C.: Liposomes as a carrier for intracellular delivery of antisense oligonucleotides: a real or magic bullet?, J Control Release, 41, 99 (1996).
• Park, J.W., Kirpotin, D.B., Hong, K., Shalaby, R., Shao, Y., Nielsen, U.B.: Tumor target- ing using anti-her2 immunoliposomes, J Control Release, 74, 95 (2001).
• Park, J.W., Hong, K., Kirpotin, D.B., Colbern, G., Shalaby, R., Baselga, J., Shao, Y., Nielsen, U.B., Marks, J.D., Moore, D., Papahadjopoulos, D., Benz C.C.: Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery, Clin Cancer Res, 8, 1172 (2002).
• Xiong, X.B., Mahmud, A., Uludag, H., Lavasanifar, A.: Multifunctional polymeric mi- celles for enhanced intracellular delivery of doxorubicin to metastatic cancer cells, Pharm Res, 25, 2555 (2008).
• Goren, D., A. Horowitz, T., Tzemach, D., Tarshish, M., Zalipsky, S., Gabizon, A.: Nu- clear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug- resistance efflux pump, Clin Cancer Res, 6, 1949 (2000).
• Weitman, S. D., Weinberg, A. G., Coney, L. R., Zurawski, V. R., Jennings, D. S., Kamen, B. A.: Cellular-localization of the folate receptor potential role in drug toxicity and fo- late homeostasis, Cancer Res, 52, 6708 (1992).
• Ross, J. F., Chaudhuri, P. K., Ratnam, M.: Differential regulation of folate receptor isoforms in normal and malignant tissues in-vivo and in established cell-lines physi- ological and clinical implications, Cancer, 732432 (1994).
• Yoo, H. S., Park, T. G.: Folate-receptor-targeted delivery of doxorubicin nano-aggregates stabilized by doxorubicin PEGfolate conjugate, J Control Release, 100, 247 (2004).
• Haley, B., Frenkel, E.: Nanoparticles for drug delivery in cancer treatment, Urol Oncol, 26, 57 (2008).
• Gradishar, W. J., Tjulandin, S., Davidson, N., Shaw, H., Desai, N., Bhar, P., Hawkins, M., O’shaughnessy, J.: Phase III trial of nanoparticle albumin-bound paclitaxel com- pared with polyethylated castor oil– based paclitaxel in women with breast cancer, J Clin Oncol, 23, 7794 2005.
• Nishioka, Y., Yoshino, H.: Lymphatic targeting with nanoparticulate System, Adv Drug Deliver Rev, 47, 55 (2001).
• Rusznyak, I., Foldi, M., Szabo, G., Lymphatics and Lymph Circulation; Physiology and Pathology, New York, Pergamon Press, (1960).
• Guyton A, Hall J. E., Textbook of medical physiology. 9th ed., Philadelphia, W.B. Saun- ders Company, (1996).
• Leak, L.V.: The structure of lymphatic capillaries in lymph formation, Fed Proc, 35, 1863 (1976).
• Trevaskis, N. L., Charman, W. N., Porter, C.J.H.: Lipid-based delivery systems and intestinal lymphatic drug transport: A mechanistic update, Adv Drug Deliver Rev, 60, 702 (2008).
• Panteleo, G., Graziosi, C., Demarest, J.F., Cohen, O.J., Vaccerezza, M., Gantt, K. , Muro-cacho, C., Fauci, A.S.: Role of lymphoid organs in the pathogenesis of human immunodefiecency virus infection, Immunol Rev, 140, 105 (1994).
• Lalanne, M., Paci, A., Andraiux, K., Clayette, P., Re, M., Vassal, G.: Synthesis and biological evaluation of two glycerolipidic prodrugs of didanosine for direct lymphatic delivery against HIV, Bioorg Med Chem Lett, 17, 2237 (2007).
• Kinman, L., Bui, T., Larsen, K., Tsai. C.C., Anderson, D., Morton, W.R., Hu, S.L., Ho, R.J.: Optimization of lipid–indinavir complexes for localization in lymphoid tissues of HIV-infected macaques, Journal of Acq Immun Def Synd, 42, 155 (2006).
• Alexa, M. R. A., Chackoa, A. J., Josea, S., Soutob, E. B.: Lopinavir loaded solid lipid nanoparticles (SLN) for intestinal lymphatic targeting, Eur J Pharm Sci, 42, 11 (2011).
• Kaur, C. D., Nahar, M., Jain, N. K.: Lymphatic targeting of zidovudine using surface- engineered liposomes, J Drug Target, 16, 798 (2008).
• Takahashi, T.: Emulsion and activated carbon in cancer chemotherapy, CRC Crit Rev Ther Drug Carrier Syst, 2, 245 (1985).
• Alitalo, K., Carmeliet, P.: Molecular mechanisms of lymphangiogenesis in health and disease, Cancer Cell, 1, 219 (2002).
• Makinen, T., Veikkola, T., Mustjoki, S., Karpanen, T., Catimel, B., Nice, E.C., Wise, L., Mercer, A., Kowalski, H., Kerjaschki. D., Stacker, S.A., Achen, M.G., Alitalo, K.: Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3, EMBO J, 20, 4762 (2001).
• Kaipainen, A., Korhonen, J., Mustonen, T., Van Hinsbergh, V.W., Fang, G.H., Dumont, D., Breitman, M., Alitalo, K. : Expression of the fms-like tyrosine kinase 4 gene be- comes restricted to lymphatic endothelium during development, Proc Natl Acad Sci, 92, 3566 (1995).
• Achen, M.G., Mann, G.B, Stacker, S.A.: Targeting lymphangiogenesis to prevent tu- mour metastasis, Brit J Cancer, 94, 1355 (2006).
• Skobe, M., Detmar, M.: Structure, function, and molecular control of the skin lym- phatic system, J Investig Dermatol Symp Proc, 5, 14 (2000).
• Achen, M.G., Roufail, S., Domagala, T., Catimel, B., Nice, E.C., Geleick, D.M., Murphy, R., Scott, A.M., Caesar, C., Makinen, T., Alitalo, K., Stacker, S.A.: Monoclonal anti- bodies to vascular endothelial growth factor-D block its interactions with both VEGF receptor-2 and VEGF receptor-3, Eur J Biochem, 267, 2505 (2000).
• Karpanen, T., Egeblad, M., Karkkainen, M.J., Kubo, H., Yla-Herttuala, S., Jaattela, M., Alitalo, K.: Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth, Cancer Res, 61, 1786 (2001).
• He, Y., Rajantie, I., Pajusola, K., Jeltsch, M., Holopainen, T., Yla-Herttuala, S., Harding, T., Jooss, K., Takahashi, T., Alitalo, K.: Vascular endothelial cell growth factor recep- tor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels, Cancer Res, 65, 4739 (2005).
• Bielenberg, D.R., Pettaway, C.A., Takashima, S., Klagsbrun, M.: Neuropilins in neo- plasms: expression, regulation, and function, Exp Cell Res, 312, 584 (2006).
• Shimizu, K., Kubo, H., Yamaguchi, K., Kawashima, K., Ueda, Y., Matsuo, K., Awane, M., Shimahara, Y., Takabayashi, A., Yamaoka, Y., Satoh, S.: Suppression of VEGFR-3 signaling inhibits lymph node metastasis in gastric cancer, Cancer Sci, 95, 328 (2004).
• Hoshida, T., Isaka, N., Hagendoorn, J., di Tomaso, E., Chen, Y.L., Pytowski, B., Fuku- mura, D., Padera, T.P., Jain, R.K.: Imaging steps of lymphatic metastasis reveals that vascular endothelial growth factor-C increases metastasis by increasing delivery of cancer cells to lymph nodes: therapeutic implications, Cancer Res, 66, 8065 (2006).
• Roberts, N., Kloos, B., Cassella, M., Podgrabinska, S., Persaud, K., Wu, Y., Pytowski, B., Skobe, M.: Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2, Cancer Res, 66, 2650 (2006).
• Kubo, H., Fujiwara, T., Jussila, L., Hashi, H., Ogawa, M., Shimizu, K., Awane, M., Sakai, Y., Takabayashi, A., Alitalo, K., Yamaoka, Y., Nishikawa, S.I.: Involvement of vascular endothelial growth factor receptor-3 in maintenance of integrity of endothelial cell lining during tumor angiogenesis, Blood, 96, 546 (2000).
• Kadambi, A., Mouta Carreira, C., Yun, C.O., Padera, T.P., Dolmans, D.E., Carmeliet, P., Fukumura, D., Jain, R.K.: Vascular endothelial growth factor (VEGF)-C differentially affects tumor vascular function and leukocyte recruitment: role of VEGF-receptor 2 and host VEGF-A, Cancer Res, 61, 2404 (2001).
• Arora, A. Scholar, E. M.: Role of tyrosine kinase inhibitors in cancer therapy, J Phar- macol Exp Ther, 315, 971 (2005).
• Yamamoto, Y., Tsutsumi, Y., Mayumi, T.: Molecular design of bioconjugated cell adhe- sion peptides with a water-soluble polymeric modifier for enhancement of antimeta- static effect, Curr Drug Targets, 3, 123 (2002).
• Adessi, C., Soto, C.: Converting a peptide into a drug: strategies to improve stability and bioavailability, Curr Med Chem, 9, 963 (2002).
• Muranishi, S., Fujita, T., Murakami, M., Yamamato, A.: Potential for lymphating target- ing of peptides, J Control Release, 46, 157 (1997).
• Laakkonen P., Porkka, K., Hoffman, J. A., Ruoslahti E.: A tumor-homing peptide with a targeting specificity related to lymphatic vessels, Nat Med, 8, 751 (2002).
• Ruoslahti E.: Drug targeting to specific vascular sites, Drug Discov Today, 7, 1138 (2002).
• Laakkonen, P., Zhang, A.L., Ruoslahti, E.: Peptide targeting of tumor lymph vessels, Ann NY Acad Sci, 1131,37 (2008).
• Luo, G., Yu, X., Jin, C., Yang, F., Fu, D., Long, J., Xu, J., Zhan, C., Lu, W.: LyP-1-con- jugated nanoparticles for targeting drug delivery to lymphatic metastatic tumors, Int J Pharm, 385, 150 (2010).
• http://www.aapsj.org/abstracts/AM_2010/W5282.pdf
• Li, X., Jin, Q., Chen, T., Zhang, B., Zheng, R., Wang, Z., Zheng H.: LyP-1 ultrasonic microbubbles targeting to cancer cell as tumor bioacoustics markers or drug carriers: targeting efficiency evaluation in microfluidic channels, Conf Proc IEEE Eng Med Biol Soc, 463 (2009).
• Laakkonen, P., Akerman, M. E., Biliran, H., Yang, M., Ferrer, F., Karpanen, T., Hoff- man, R. M., Ruoslahti, E., Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells, Proc Natl Acad Sci, 101, 9381 (2004).
• Yang, F., Fu D. L., Long, J., Ni X., Q.: Magnetic lymphatic targeting drug delivery sys- tem using carbon nanotubes, Medical Hypotheses, 70, 765, (2008).
• Widder K.J., Marino P.A., Morris R.M., Senyei A.E., “Magnetically Modulated Nanosys- tems: A Unique Drug-Delivery Platform: Characterization of Magnetic-targeted Carri- ers”, Targeted Drugs., Goldberg E (Ed), New York, John Wiley and Sons, (1983).
• Lubbe, A. S., Alexiou, C., Bergemann, C.: Clinical application of magnetic drug target- ing, J Surg Res, 95, 200 (2001).
• Oussoren, C., Storm, G.: Liposomes to target the lymphatics by subcutaneous admin- istration, Adv Drug Deliver Rev, 50, 143 (2001).
• Liu, J., Meisner, D., Kwong, E., Wu, X.Y., Johnston, M.R.: A novel trans-lymphatic drug delivery system: Implantable gelatin sponge impregnated with PLGA–paclitaxel micro- spheres, Biomaterials, 28, 3236 (2007).
• Hashida, M., Egawa, M., Muranishi, S., Sezaki, H.: Role of intra-muscular administra- tion of water-in-oil emulsions as a method for increasing the delivery of anticancer agents to regional lymphatics, J Pharmacokin Biopharm, 5, 223 (1997).
• Kaminskasa, L.M., Kotaa, J., McLeoda, V.M., Kellyb B.D, Karellasb, P., Portera, C.J.H.: PEGylation of polylysine dendrimers improves absorption and lymphatic targeting fol- lowing sc administration in rats, J Control Release, 140, 108 (2009).
• Ehrlich P.: On immunity with specific reference to cell life, Proc R Soc London, 66, 429 (1900).